The STORM-PE trial data showed that computer-assisted vacuum thrombectomy (CAVT) combined with anticoagulation resulted in significantly better functional outcomes compared to anticoagulation alone. After 90 days, patients treated with CAVT achieved greater walking distances and a higher proportion reached NYHA Class I (no physical limitations).
LIXTE Biotechnology has announced favorable clinical data from a study evaluating its lead compound, LB-100, in combination with GSK's Dostarlimab for ovarian cancer patients. The results, presented at the Annual Society of Gynecological Care Conference, demonstrate the potential of this combination therapy to enhance…
Read the full storyMedtronic (MDT) has entered into a strategic distribution agreement with Merit Medical Systems (MMSI) for the ViaVerte system. The ViaVerte system is an FDA-cleared, implant-free technology designed for basivertebral nerve ablation (BVNA) to treat chronic lower back pain. This partnership aims to address the rising…
Microbot Medical Inc. (Nasdaq: MBOT) has officially transitioned from a limited market release to a full market release of its LIBERTY Endovascular Robotic System across the United States. The announcement was made during the Society of Interventional Radiology (SIR) Annual Scientific Meeting, marking a significant…
Penumbra, Inc. (NYSE: PEN) announced positive 90-day results from its STORM-PE randomized controlled trial, highlighting the clinical superiority of its Computer Assisted Vacuum Thrombectomy (CAVT) technology. The data revealed that CAVT combined with anticoagulation therapy resulted in significantly better functional…